JP2024009951A5 - - Google Patents
Info
- Publication number
- JP2024009951A5 JP2024009951A5 JP2023176874A JP2023176874A JP2024009951A5 JP 2024009951 A5 JP2024009951 A5 JP 2024009951A5 JP 2023176874 A JP2023176874 A JP 2023176874A JP 2023176874 A JP2023176874 A JP 2023176874A JP 2024009951 A5 JP2024009951 A5 JP 2024009951A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- weeks
- composition
- reduction
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809327P | 2019-02-22 | 2019-02-22 | |
| US62/809,327 | 2019-02-22 | ||
| US201962814441P | 2019-03-06 | 2019-03-06 | |
| US62/814,441 | 2019-03-06 | ||
| US201962833517P | 2019-04-12 | 2019-04-12 | |
| US62/833,517 | 2019-04-12 | ||
| PCT/US2020/019167 WO2020172501A1 (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| JP2021549571A JP7789561B2 (ja) | 2019-02-22 | 2020-02-21 | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549571A Division JP7789561B2 (ja) | 2019-02-22 | 2020-02-21 | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024009951A JP2024009951A (ja) | 2024-01-23 |
| JP2024009951A5 true JP2024009951A5 (https=) | 2026-01-19 |
Family
ID=72141382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549571A Active JP7789561B2 (ja) | 2019-02-22 | 2020-02-21 | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| JP2023176874A Pending JP2024009951A (ja) | 2019-02-22 | 2023-10-12 | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549571A Active JP7789561B2 (ja) | 2019-02-22 | 2020-02-21 | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US11058670B2 (https=) |
| EP (1) | EP3927345A4 (https=) |
| JP (2) | JP7789561B2 (https=) |
| KR (2) | KR20210118971A (https=) |
| CN (1) | CN113490496A (https=) |
| AU (1) | AU2020226863B2 (https=) |
| BR (1) | BR112021015129A2 (https=) |
| CA (1) | CA3131263C (https=) |
| CL (1) | CL2021002145A1 (https=) |
| IL (1) | IL285771A (https=) |
| MX (1) | MX2021010135A (https=) |
| NZ (1) | NZ778399A (https=) |
| PH (1) | PH12021552025A1 (https=) |
| SG (1) | SG11202108964YA (https=) |
| UA (1) | UA129592C2 (https=) |
| WO (1) | WO2020172501A1 (https=) |
| ZA (1) | ZA202105633B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| ES3008837T3 (en) * | 2018-12-21 | 2025-03-25 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907349A (zh) * | 2021-02-10 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| US20230372312A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| AU2023403359A1 (en) * | 2022-11-30 | 2025-05-29 | Corcept Therapeutics Incorporated | Treatments for cushing's syndrome that do not significantly affect cardiac rhythms |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (https=) | 1954-11-30 | 1957-04-11 | ||
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| JPH09505030A (ja) | 1993-08-06 | 1997-05-20 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | ヒドロイソキノリン誘導体 |
| US5696130A (en) | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
| EP1512683B1 (en) | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| US7238778B2 (en) | 2001-07-17 | 2007-07-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| AU2002319665B2 (en) | 2001-07-23 | 2006-09-21 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| CA2473886C (en) | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CN1665515A (zh) | 2002-07-02 | 2005-09-07 | 科塞普特治疗公司 | 治疗与干扰素α治疗相关的精神病的方法 |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| UA84881C2 (ru) | 2003-09-03 | 2008-12-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его |
| PT1761497E (pt) | 2004-01-09 | 2008-09-25 | Corcept Therapeutics Inc | Azadecalinas moduladoras do receptor de glucocorticóides |
| AU2005217646A1 (en) | 2004-02-26 | 2005-09-09 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A novel cofactor that modulates steroid receptor activities |
| AU2005222421B2 (en) | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| EP1928840B1 (en) | 2005-04-05 | 2011-08-10 | F. Hoffmann-La Roche AG | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| WO2009058944A2 (en) | 2007-11-01 | 2009-05-07 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| US20090156672A1 (en) | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20100135956A1 (en) | 2008-11-21 | 2010-06-03 | Auspex Pharmaceuticals, Inc. | Steroid modulators of progesterone receptor and/or glucocorticoid receptor |
| ES2531040T3 (es) | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| KR20130106378A (ko) | 2010-08-27 | 2013-09-27 | 코어셉트 쎄라퓨틱스, 잉크. | 피리딜-아민 융합된 아자데칼린 조절제 |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| RS57157B1 (sr) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitori i njihove primene |
| EP3111950B1 (en) | 2012-02-24 | 2021-08-25 | The University of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| PT4119561T (pt) | 2012-05-25 | 2024-09-30 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona |
| FI3848027T3 (fi) * | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| CN107530435A (zh) | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| ES3008837T3 (en) * | 2018-12-21 | 2025-03-25 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of a glucocorticoid receptor modulator |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
-
2020
- 2020-02-21 JP JP2021549571A patent/JP7789561B2/ja active Active
- 2020-02-21 MX MX2021010135A patent/MX2021010135A/es unknown
- 2020-02-21 NZ NZ778399A patent/NZ778399A/en unknown
- 2020-02-21 BR BR112021015129-0A patent/BR112021015129A2/pt not_active Application Discontinuation
- 2020-02-21 US US16/797,421 patent/US11058670B2/en active Active
- 2020-02-21 KR KR1020217030352A patent/KR20210118971A/ko not_active Ceased
- 2020-02-21 EP EP20759882.2A patent/EP3927345A4/en active Pending
- 2020-02-21 UA UAA202105300A patent/UA129592C2/uk unknown
- 2020-02-21 SG SG11202108964YA patent/SG11202108964YA/en unknown
- 2020-02-21 WO PCT/US2020/019167 patent/WO2020172501A1/en not_active Ceased
- 2020-02-21 CA CA3131263A patent/CA3131263C/en active Active
- 2020-02-21 PH PH1/2021/552025A patent/PH12021552025A1/en unknown
- 2020-02-21 KR KR1020257016944A patent/KR20250076696A/ko active Pending
- 2020-02-21 AU AU2020226863A patent/AU2020226863B2/en active Active
- 2020-02-21 CN CN202080015826.9A patent/CN113490496A/zh active Pending
-
2021
- 2021-06-09 US US17/343,524 patent/US11590113B2/en active Active
- 2021-08-10 ZA ZA2021/05633A patent/ZA202105633B/en unknown
- 2021-08-13 CL CL2021002145A patent/CL2021002145A1/es unknown
- 2021-08-22 IL IL285771A patent/IL285771A/en unknown
-
2022
- 2022-12-20 US US18/084,866 patent/US11684612B2/en active Active
-
2023
- 2023-05-09 US US18/144,979 patent/US12097192B2/en active Active
- 2023-10-12 JP JP2023176874A patent/JP2024009951A/ja active Pending
-
2024
- 2024-07-19 US US18/777,823 patent/US20250009721A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024009951A5 (https=) | ||
| Walsh et al. | Epsilon‐Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial | |
| JP2021181478A (ja) | 貧血治療のための組成物及び方法 | |
| EP1071430B1 (en) | Treatment of iatrogenic and age-related hypertension with vitamin b6 derivatives and pharmaceutical compositions useful therein | |
| Mimran et al. | Effect of captopril on renal vascular tone in patients with essential hypertension | |
| JP2015526458A5 (https=) | ||
| JP4569106B2 (ja) | 臓器線維化抑制剤 | |
| JP5788527B2 (ja) | キナーゼ阻害剤の副作用低減剤 | |
| JP2023522010A5 (https=) | ||
| JP2019206562A (ja) | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 | |
| JP2018516951A (ja) | 夜間胃酸過分泌に対するベンズイミダゾール誘導体の使用 | |
| JP2024531188A5 (https=) | ||
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| JP2008542380A (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| WO2022182982A1 (en) | Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor | |
| JP4786127B2 (ja) | 色素沈着改善治療薬 | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| JP2006505548A (ja) | Ｐｐａｒリガンドと抗酸化剤の会合および肥満の治療のためのその使用 | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| TW202308648A (zh) | 治療貧血之方法 | |
| JP2024529777A (ja) | ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用 | |
| EP1726303A1 (en) | Therapeutic agent for renal anemia | |
| CN120093759B (zh) | 一种预防或治疗动脉硬化的药物组合物及其应用 | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| CN101370520A (zh) | 用于心力衰竭的预防或治疗的医药组合物 |